Alberta-based Applied Pharmaceutical Innovation has partnered with IRICoR, a Quebec-based Centre of Excellence in Commercialization and Research specialized in drug discovery, to expand drug discovery, development, and commercialization opportunities in Canada.
IRICoR’s expertise in de-risking early-stage novel therapies, combined with API’s expertise in translational science and later-stage development will help accelerate the commercialization of life-saving treatments for patients across the country. The partnership will allow API and IRICoR to support each other’s efforts in the development of a broader and more vibrant pan-Canadian life sciences ecosystem.
“IRICoR has a long track record of successfully de-risking early-stage, potential new therapies for diseases with high unmet medical need with a view to establishing partnerships with biopharmaceutical companies and investors in order to advance these programs to the clinic,” commented Steven Klein, Vice-President, Business Development, at IRICoR. “We look forward to collaborating with API to further increase our ability to develop innovative drug discovery projects that will lead to new therapies for Canadian patients suffering from life-threatening diseases.”
“API focuses on empowering commercial development in the Canadian life sciences industry. The partnership between API and IRICoR builds a strong and sustainable infrastructure for companies to develop and grow their solutions in Canada. The extensive networks and expertise behind each organization will provide companies with access to state-of-the-art facilities and extensive knowledge needed to navigate the sector,” said Andrew MacIsaac, CEO at API.
About the Partners
API is a not-for-profit that works in collaboration with the University of Alberta’s Faculty of Pharmacy and Pharmaceutical Sciences as well as research and post-secondary institutions across Canada in a network that includes global top 15 expertise in applied pharmaceutical sciences and commercial drug development, with the stated goal of building a sustainable and vibrant pharmaceutical sector in Canada and establishing Alberta as a world-leading hub for life sciences innovation and commercialization.
IRICoR is a not-for-profit and Centre of Excellence in Commercialization and Research specialized in drug discovery, and a key player in the sector both nationally and internationally, playing an increasingly pivotal role in the development of novel therapies in cancer and related areas, with the stated goal to facilitate and accelerate the transformation of research results into innovation for the benefit of patients.